v3.25.2
Segment and Geographic Information
 6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Segment and Geographic Information Segment and Geographic Information
The Company operates in one segment: pharmaceutical products. Its chief operating decision maker is the Chief Executive Officer, who makes operating decisions, assesses performance and allocates resources on a consolidated basis.
The primary measure of segment profitability for the Company’s operating segment is considered to be consolidated net income (loss). Significant segment expenses reviewed by the CODM on a regular basis included within net income (loss) include cost of product sales, research and development expenses and selling, general and administrative expenses which are separately presented on the Company’s consolidated statements of operations. Other segment items within net income (loss) include interest income, net, other income (expense), net and income tax expense.
The Company’s long-lived assets are primarily located in the U.S. and China.
Net product revenues by geographic area are based upon the location of the customer, and net collaboration revenue is recorded in the jurisdiction in which the related income is expected to be sourced from. Total revenues by geographic area are presented as follows:
 Three Months EndedSix Months Ended
 June 30,June 30,
 2025202420252024
 $$$$
U.S. - total revenue694,427 481,430 1,261,638 832,886 
Product revenue685,395 479,365 1,248,743 830,821 
Collaboration revenue9,032 2,065 12,895 2,065 
China - total revenue432,924 352,070 832,516 672,446 
Product revenue428,802 347,112 825,164 662,774 
Collaboration revenue4,122 4,958 7,352 9,672 
Europe - total revenue152,384 82,389 270,938 149,249 
Product revenue152,314 81,392 269,212 148,232 
Collaboration revenue70 997 1,726 1,017 
Rest of world - total revenue35,565 13,277 67,487 26,237 
Product revenue35,565 13,277 67,487 26,237 
Total Revenue1,315,300 929,166 2,432,579 1,680,818